Myriad Genetics MYGN Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 69.9%0.0pp | 69.9%+1.2pp | 68.6%-1.6pp | 70.2%— | |
| Operating margin | -47%-32.2pp | -14.7%+19.4pp | -34.2%-13.4pp | -20.7%+6.9pp | |
| Net margin | -44.4%-29.2pp | -15.2%+19.8pp | -35%-18.4pp | -16.5%-12.6pp | |
| Returns | |||||
| Return on equity | -68.5%-51.3pp | -17.2%+14.4pp | -31.6%-19.5pp | -12.1%-9.1pp | |
| Return on invested capital | -67%-50.8pp | -16.2%+13.1pp | -29.3%-13.3pp | -15.9%+4.6pp | |
| Efficiency | |||||
| Asset turnover | 1×+0.2× | 0.8×+0.1× | 0.6×+0.1× | 0.5×0.0× | |
| Liquidity | |||||
| Current ratio | 2.5×+0.7× | 1.8×-0.2× | 2×0.0× | 2×-0.4× | |
| Leverage | |||||
| Debt-to-equity | 0.6×+0.4× | 0.2×0.0× | 0.2×0.0× | 0.2×+0.1× | |
| Per Share | |||||
| Book value per share | $3.97-48.6% | $7.74-18.2% | $9.46-13.9% | $10.99-11.4% | |
| Valuation | |||||
| Market capitalization | $512.85M+13.1% | $1.25B-20.2% | $1.56B+33.0% | $1.18B-46.7% | |
| Price / sales | 0.6×+0.1× | 1.5×-0.6× | 2.1×+0.3× | 1.7×-1.5× | |
| Price / book | 1.5×+0.9× | 1.8×-0.2× | 2×+0.7× | 1.3×-0.9× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Myriad Genetics's profit margins?
- Myriad Genetics (MYGN) runs a 70.0% gross margin and a -46.9% operating margin, with a -48.2% net margin.
- Where do Myriad Genetics's ratios come from?
- Every ratio is computed from Myriad Genetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
